Systemic propranolol reduces b-wave amplitude in the ERG and increases IGF-1 receptor phosphorylation in rat retina

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 5, 2010, Pages 2730-2735

  Jiang, Youde ^a   Steinle, Jena J ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHENTOLAMINE; PROPRANOLOL; PROTEIN KINASE B; SODIUM CHLORIDE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C RECEPTOR; VASCULOTROPIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; MITOGEN ACTIVATED PROTEIN KINASE 6; TYROSINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; B WAVE; CONTROLLED STUDY; ELECTRORETINOGRAPHY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; RETINA; SIGNAL TRANSDUCTION; SYSTEMIC THERAPY; TREATMENT DURATION; ANIMAL; DRUG DELIVERY SYSTEM; DRUG EFFECT; METABOLISM; PHOSPHORYLATION; SPRAGUE DAWLEY RAT; WESTERN BLOTTING;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BLOTTING, WESTERN; DRUG DELIVERY SYSTEMS; ELECTRORETINOGRAPHY; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASE 6; PHOSPHORYLATION; PROPRANOLOL; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, IGF TYPE 1; RETINA; TYROSINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77952476952     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-4779     Document Type: Article

References (52)

1. Smith CP, Sharma S, Steinle JJ. Age-related changes in sympathetic neurotransmission in rat retina and choroid. Exp Eye Res. 2007; 84:75-81.
2. Jiang Y, Walker RJ, Steinle JJ. Age-associated increase in cleaved caspase 3 despite phosphorylation of IGF-1 receptor in the rat retina. J Gerontol A Biol Sci Med Sci. 2009;64:1154-1159.
3. Smith CP, Steinle JJ. Changes in growth factor expression in normal aging of the rat retina. Exp Eye Res. 2007;85:817-824.
4. Holzenberger M. The GH/IGF-I axis and longevity. Eur J Endocrinol. 2004;151(suppl 1):S23-S27.
5. Bartke A. Impact of reduced insulin-like growth factor-1/insulin signaling on aging in mammals: novel findings. Aging Cell. 2008; 7:285-290.
6. Ramsey MM, Ingram RL, Cashion AB, et al. Growth hormonedeficient dwarf animals are resistant to dimethylbenzanthracine (DMBA)-induced mammary carcinogenesis. Endocrinology. 2002; 143:4139-4142.
7. Kenyon C. The plasticity of aging: insights from long-lived mutants. Cell. 2005;120:449-460.
8. Allen TR, Krueger KD, Hunter WJ 3rd, Agrawal DK. Evidence that insulin-like growth factor-1 requires protein kinase C-epsilon, PI3-kinase and mitogen-activated protein kinase pathways to protect human vascular smooth muscle cells from apoptosis. Immunol Cell Biol. 2005;83:651-667.
9. O'Connor JC, McCusker RH, Strle K, Johnson RW, Dantzer R, Kelley KW. Regulation of IGF-I function by proinflammatory cytokines: at the interface of immunology and endocrinology. Cell Immunol. 2008;252:91-110.
10. Smith LE. IGF-1 and retinopathy of prematurity in the preterm infant. Biol Neonate. 2005;88:237-244.
11. Seigel GM, Lupien SB, Campbell LM, Ishii DN. Systemic IGF-I treatment inhibits cell death in diabetic rat retina. J Diabetes Complications. 2006;20:196-204.
12. Simo R, Carrasco E, Garcia-Ramirez M, Hernandez C. Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr Diabetes Rev. 2006;2:71-98.
13. Koriyama Y, Homma K, Sugitani K, et al. Upregulation of IGF-I in the goldfish retinal ganglion cells during the early stage of optic nerve regeneration. Neurochem Int. 2007;50:749-756.
14. Hwa V, Oh Y, Rosenfeld RG. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev. 1999;20:761-787.
15. Ugarte M, Hussain AA, Marshall J. An experimental study of the elastic properties of the human Bruch's membrane-choroid complex: relevance to ageing. Br J Ophthalmol. 2006;90:621-626.
16. Verzar F. The ageing of connective tissue. Gerontologia. 1957;1:363-378.
17. Miyamura N, Mishima K, Honda S, et al. Age and topographic variation of insulin-like growth factor-binding protein 2 in the human RPE. Invest Ophthalmol Vis Sci. 2001;42:1626-1630.
18. Yang H, Chaum E. A reassessment of insulin-like growth factor binding protein gene expression in the human retinal pigment epithelium. J Cell Biochem. 2003;89:933-943.
19. King JL, Guidry C. Muller cell production of insulin-like growth factor-binding proteins in vitro: modulation with phenotype and growth factor stimulation. Invest Ophthalmol Vis Sci. 2004;45:4535-4542.
20. Spoerri PE, Ellis EA, Tarnuzzer RW, Grant MB. Insulin-like growth factor: receptor and binding proteins in human retinal endothelial cell cultures of diabetic and nondiabetic origin. Growth Horm IGF Res. 1998;8:125-132.
21. Walker R, Steinle J. Role of beta-adrenergic receptors in inflammatory marker expression in Muller cells. Invest Ophthalmol Vis Sci. 2007;48:5276-5281.
22. Steinle JJ, Chin VC, Williams KP, Panjala SR. Beta-adrenergic receptor stimulation modulates iNOS protein levels through p38 and ERK1/2 signaling in human retinal endothelial cells. Exp Eye Res. 2008;87:30-34.
23. Steinle JJ, Booz GW, Meininger CJ, Day JN, Granger HJ. Beta 3-adrenergic receptors regulate retinal endothelial cell migration and proliferation. J Biol Chem. 2003;278:20681-20686.
24. Chesik D, Glazenburg L, De Keyser J, Wilczak N. Enhanced proliferation of astrocytes from beta(2)-adrenergic receptor knockout mice is influenced by the IGF system. J Neurochem. 2007;100:1555-1564.
25. Baltensperger K, Karoor V, Paul H, Ruoho A, Czech MP, Malbon CC. The beta-adrenergic receptor is a substrate for the insulin receptor tyrosine kinase. J Biol Chem. 1996;271:1061-1064.
26. Steinle JJ, Smith PG. Role of adrenergic receptors in vascular remodelling of the rat choroid. Br J Pharmacol. 2002;136:730-734.
27. Greenberg S, Wilborn WM. Effect of chronic administration of clonidine and propranolol on the myocardium of spontaneously hypertensive rats. Arch Int Pharmacodyn Ther. 1982;255:141-161.
28. Holmang A, Jennische E, Bjorntorp P. The effects of long-term hyperinsulinaemia on insulin sensitivity in rats. Acta Physiol Scand. 1995;153:67-73.
29. Forte JD, Bui BV, Vingrys AJ. Wavelet analysis reveals dynamics of rat oscillatory potentials. J Neurosci Methods. 2007;169:191-200.
30. Weymouth AE, Vingrys AJ. Rodent electroretinography: methods for extraction and interpretation of rod and cone responses. Prog Retin Eye Res. 2008;27:1-44.
31. Steinle JJ. Sympathetic neurotransmission modulates expression of inflammatory markers in the rat retina. Exp Eye Res. 2007;84:118-125.
32. Rosenfeld RG, Charles T Roberts J. The IGF System: Molecular Biology, Physiology, and Clinical Application. Totowa, NJ: Humana Press; 1999.
33. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol. 2002;29:10-14.
34. Qaum T, Xu Q, Joussen AM, et al. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci. 2001;42:2408-2413.
35. Murata T, Ishibashi T, Khalil A, Hata Y, Yoshikawa H, Inomata H. Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels. Ophthalmic Res. 1995;27:48-52.
36. Murata M, Kador PF, Sato S. Vascular endothelial growth factor (VEGF) enhances the expression of receptors and activates mitogen-activated protein (MAP) kinase of dog retinal capillary endothelial cells. J Ocul Pharmacol Ther. 2000;16:383-391.
37. Spaide RF. Rationale for combination therapies for choroidal neovascularization. Am J Ophthalmol. 2006;141:149-156.
38. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol. 1997;81:154-162.
39. Ruberte J, Ayuso E, Navarro M, et al. Increased ocular levels of IGF-1 in transgenic mice lead to diabetes-like eye disease. J Clin Invest. 2004;113:1149-1157.
40. Bartke A, Chandrashekar V, Dominici F, et al. Insulin-like growth factor 1 (IGF-1) and aging: controversies and new insights. Biogerontology. 2003;4:1-8.
41. Feldman EL, Randolph AE. Regulation of insulin-like growth factor binding protein synthesis and secretion in human retinal pigment epithelial cells. J Cell Physiol. 1994;158:198-204.
42. Suzuki J, Ohno I, Nawata J, Miura S, Ikeda J, Shirato K. Overexpression of insulin-like growth factor-I in hearts of rats with isoproterenol-induced cardiac hypertrophy. J Cardiovasc Pharmacol. 1999;34:635-644.
43. Lembo G, Rockman HA, Hunter JJ, et al. Elevated blood pressure and enhanced myocardial contractility in mice with severe IGF-1 deficiency. J Clin Invest. 1996;98:2648-2655.
44. Miura S, Ohno I, Suzuki J, et al. Inhibition of matrix metalloproteinases prevents cardiac hypertrophy induced by beta-adrenergic stimulation in rats. J Cardiovasc Pharmacol. 2003;42:174-181.
45. Sodhi A, Montaner S, Miyazaki H, Gutkind JS. MAPK and Akt act cooperatively but independently on hypoxia inducible factor-1alpha in rasV12 upregulation of VEGF. Biochem Biophys Res Commun. 2001;287:292-300.
46. Punglia RS, Lu M, Hsu J, et al. Regulation of vascular endothelial growth factor expression by insulin-like growth factor I. Diabetes. 1997;46:1619-1626.
47. Hirooka K, Kelly ME, Baldridge WH, Barnes S. Suppressive actions of betaxolol on ionic currents in retinal ganglion cells may explain its neuroprotective effects. Exp Eye Res. 2000;70:611-621.
48. Wood JP, Schmidt KG, Melena J, Chidlow G, Allmeier H, Osborne NN. The beta-adrenoceptor antagonists metipranolol and timolol are retinal neuroprotectants: comparison with betaxolol. Exp Eye Res. 2003;76:505-516.
49. Osborne NN, Wood JP, Chidlow G. Invited review: neuroprotective properties of certain beta-adrenoceptor antagonists used for the treatment of glaucoma. J Ocul Pharmacol Ther. 2005;21:175-181.
50. Phipps JA, WilkinsonBerka JL, Fletcher EL. Retinal dysfunction in diabetic ren-2 rats is ameliorated by treatment with valsartan but not atenolol. Invest Ophthalmol Vis Sci. 2007;48:927-934.
51. WilkinsonBerka JL, Tan G, Jaworski K, Ninkovic S. Valsartan but not atenolol improves vascular pathology in diabetic Ren-2 rat retina. Am J Hypertens. 2007;20:423-430.
52. Williams KP, Steinle JJ. Maintenance of beta-adrenergic receptor signaling can reduce Fas signaling in human retinal endothelial cells. Exp Eye Res. 2009;89:448-455.